Furaprofen

Furaprofen (R803) is an effective HCV replication inhibitor. Furaprofen (R803) is substantially more potent against genotype 1a and 1b replicons ( EC 50 , ~30 nM) than against the genotype 2a replicon (EC 50 , ~1,000 nM). In Vitro Furaprofen (R803) is potent and highly specific for HCV replication. The antiviral activity of Furaprofen has been determined by a reporter replicon assay with multiple repeats to be 29.88±8.05 nM, an ~3-fold improvement over the activity of the parent compound, R706. The potency of Furaprofen against the replicon is also confirmed by both Western blotting and TaqMan RT-PCR to be about 37 nM and 54.67±4.11 nM, respectively. To assess the general effect of Furaprofen on cell proliferation, a panel of primary cells and transformed human cell lines are treated with increasing doses of Furaprofen for 48 h, and the effect on cell proliferation is measured by an MTS-based cell viability assay. The the concentration that caused a 50% reduction in cell numbers in the absence of virus infection (CC 50 ) of Furaprofen is found to range from 2 μM to ≥10 μM, depending on the cell type and proliferation status. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:EC50: ~30 nM (HCV genotype 1a and 1b replicons), ~1000 nM (HCV genotype 2a replicon)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet